JACKSONVILLE, Fla., July 30, 2026
Medical Microinstruments (MMI) announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Investigational Device Exemption (IDE) for its REMIND (Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease) study, allowing the trial to advance to Phase II of patient enrollment. The approval follows the FDA’s review of 30-day safety data from the initial cohort of patients and permits expansion from up to five participants to the full early feasibility study (EFS) population of 15 patients. The study is evaluating the Symani® Surgical System and robotic microsurgical techniques designed to restore lymphatic drainage pathways in the deep cervical lymph nodes (dCLNs) of patients with Alzheimer’s disease and confirmed lymphatic abnormalities. The milestone marks an important step in exploring whether robotic-enabled microsurgery can offer a novel therapeutic approach for neurodegenerative diseases.
REMIND Study Expands Following Positive Early Safety Review
The REMIND study is a global, prospective early feasibility trial designed to assess the safety and feasibility of using the Symani Surgical System for microsurgical reconstruction of lymphatic drainage pathways associated with Alzheimer’s disease. Following a favorable review of 30-day safety outcomes in the initial patient cohort, the FDA approved continued enrollment into the full 15-patient EFS. Investigators are evaluating whether restoring lymphatic function in the deep cervical lymph nodes could improve the clearance of waste products from the brain, an emerging area of research in Alzheimer’s disease. The study represents one of the first clinical investigations to assess the role of robotic microsurgery in treating a neurodegenerative disorder.
Symani Surgical System Targets Precision Microsurgery
The Symani® Surgical System is a robotic-assisted microsurgery platform developed to enhance precision during soft tissue and microvascular procedures. The system combines the world’s smallest wristed microinstruments with motion scaling and tremor reduction technologies, enabling surgeons to perform procedures at a microscopic level beyond the limits of conventional manual techniques. While the platform is FDA-authorized for specific microsurgical applications, its use in lymphatic reconstruction for brain diseases, including Alzheimer’s disease, remains investigational. Through the REMIND study, researchers aim to generate critical clinical evidence supporting the potential application of robotic microsurgery in neurological disorders.
Advertisement
Study Findings Could Shape Future Alzheimer’s Research
MMI stated that data generated from the REMIND early feasibility study will help guide future clinical development, including the design of a larger pivotal trial if the technology demonstrates favorable safety and feasibility outcomes. Company leadership emphasized that the FDA’s approval to expand enrollment reflects continued progress toward evaluating whether robotic-assisted lymphatic reconstruction can become a new treatment strategy for patients with Alzheimer’s disease. As one of several ongoing clinical programs involving the Symani Surgical System, the REMIND study also supports MMI’s broader goal of expanding the use of robotic microsurgery into emerging therapeutic areas where precision surgery may improve patient outcomes.
Source:MMI ,press release
